# Martin Marietta Materials Inc: financial statements, quarterly

MLM · NYSE · CIK 916076 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mlm.md) · [Financials](/companies/mlm/financials.md) · [Filings](/companies/mlm/filings.md) · [Insiders](/companies/mlm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mlm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,994](/filings/0000950170-24-118821.md) | [682 d](/filings/0001193125-26-059193.md) | [1,056](/filings/0001193125-26-059193.md) | [1,552](/filings/0001193125-26-059193.md) | [1,642](/filings/0001193125-26-059193.md) | [1,412](/filings/0001193125-26-059193.md) | [1,162](/filings/0001193125-26-196029.md) | [1,609](/filings/0001193125-26-326001.md) | [1,846](/filings/0001193125-26-059193.md) | [1,534](/filings/0001193125-26-059193.md) | [1,362](/filings/0001193125-26-196029.md) | [1,947](/filings/0001193125-26-326001.md) |
| Cost of revenue | $m | [1,318](/filings/0000950170-24-118821.md) | [476 d](/filings/0001193125-26-059193.md) | [979](/filings/0000950170-25-060940.md) | [1,247](/filings/0000950170-25-105060.md) | [1,129](/filings/0001193125-25-264566.md) | [987 d](/filings/0001193125-26-059193.md) | [847](/filings/0001193125-26-196029.md) | [1,113](/filings/0001193125-26-326001.md) | [1,235](/filings/0001193125-25-264566.md) | [1,066 d](/filings/0001193125-26-059193.md) | [1,052](/filings/0001193125-26-196029.md) | [1,452](/filings/0001193125-26-326001.md) |
| Gross profit | $m | [676](/filings/0000950170-24-118821.md) | [206 d](/filings/0001193125-26-059193.md) | [250](/filings/0001193125-26-059193.md) | [449](/filings/0001193125-26-059193.md) | [513](/filings/0001193125-26-059193.md) | [424](/filings/0001193125-26-059193.md) | [315](/filings/0001193125-26-196029.md) | [496](/filings/0001193125-26-326001.md) | [611](/filings/0001193125-26-059193.md) | [468](/filings/0001193125-26-059193.md) | [310](/filings/0001193125-26-196029.md) | [495](/filings/0001193125-26-326001.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [108](/filings/0000950170-24-118821.md) | [101 d](/filings/0001193125-26-059193.md) | [118](/filings/0000950170-25-060940.md) | [117](/filings/0000950170-25-105060.md) | [101](/filings/0001193125-25-264566.md) | [101 d](/filings/0001193125-26-059193.md) | [125](/filings/0001193125-26-196029.md) | [104](/filings/0001193125-26-326001.md) | [110](/filings/0001193125-25-264566.md) | [103 d](/filings/0001193125-26-059193.md) | [133](/filings/0001193125-26-196029.md) | [116](/filings/0001193125-26-326001.md) |
| Operating income | $m | [567](/filings/0000950170-24-118821.md) | [107 d](/filings/0001193125-26-059193.md) | [1,421](/filings/0000950170-25-060940.md) | [398](/filings/0000950170-25-105060.md) | [406](/filings/0001193125-25-264566.md) | [339 d](/filings/0001193125-26-059193.md) | [179](/filings/0001193125-26-196029.md) | [413](/filings/0001193125-26-326001.md) | [505](/filings/0001193125-25-264566.md) | [341 d](/filings/0001193125-26-059193.md) | [162](/filings/0001193125-26-196029.md) | [372](/filings/0001193125-26-326001.md) |
| Interest expense | $m | [41.0](/filings/0000950170-24-118821.md) | [40.0 d](/filings/0001193125-26-059193.md) | [40.0](/filings/0000950170-25-060940.md) | [40.0](/filings/0000950170-25-105060.md) | [38.0](/filings/0001193125-25-264566.md) | [51.0 d](/filings/0001193125-26-059193.md) | [56.0](/filings/0001193125-26-196029.md) | [57.0](/filings/0001193125-26-326001.md) | [59.0](/filings/0001193125-25-264566.md) | [58.0 d](/filings/0001193125-26-059193.md) | [56.0](/filings/0001193125-26-196029.md) | [59.0](/filings/0001193125-26-326001.md) |
| Income tax | $m | [110](/filings/0000950170-24-118821.md) | [(3.0) d](/filings/0001193125-26-059193.md) | [368](/filings/0000950170-25-060940.md) | [78.0](/filings/0000950170-25-105060.md) | [77.0](/filings/0001193125-25-264566.md) | [46.0 d](/filings/0001193125-26-059193.md) | [28.0](/filings/0001193125-26-196029.md) | [73.0](/filings/0001193125-26-326001.md) | [89.0](/filings/0001193125-25-264566.md) | [46.0 d](/filings/0001193125-26-059193.md) | [38.0](/filings/0001193125-26-196029.md) | [64.0](/filings/0001193125-26-326001.md) |
| Net income | $m | [417](/filings/0000950170-24-118821.md) | [283 d](/filings/0001193125-26-059193.md) | [1,045](/filings/0001193125-26-059193.md) | [293](/filings/0001193125-26-059193.md) | [363](/filings/0001193125-26-059193.md) | [294](/filings/0001193125-26-059193.md) | [116](/filings/0001193125-26-196029.md) | [328](/filings/0001193125-26-326001.md) | [414](/filings/0001193125-26-059193.md) | [279](/filings/0001193125-26-059193.md) | [1,513](/filings/0001193125-26-196029.md) | [251](/filings/0001193125-26-326001.md) |
| Diluted EPS | $ per share | [6.72](/filings/0000950170-24-118821.md) | not reported | [16.87](/filings/0000950170-25-060940.md) | [4.76](/filings/0000950170-25-105060.md) | [5.91](/filings/0001193125-25-264566.md) | not reported | [1.90](/filings/0001193125-26-196029.md) | [5.43](/filings/0001193125-26-326001.md) | [6.85](/filings/0001193125-25-264566.md) | not reported | [25.06](/filings/0001193125-26-196029.md) | [4.17](/filings/0001193125-26-326001.md) |
| Basic EPS | $ per share | [6.74](/filings/0000950170-24-118821.md) | not reported | [16.92](/filings/0000950170-25-060940.md) | [4.77](/filings/0000950170-25-105060.md) | [5.93](/filings/0001193125-25-264566.md) | not reported | [1.91](/filings/0001193125-26-196029.md) | [5.44](/filings/0001193125-26-326001.md) | [6.86](/filings/0001193125-25-264566.md) | not reported | [25.11](/filings/0001193125-26-196029.md) | [4.18](/filings/0001193125-26-326001.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.6](/filings/0000950170-23-057372.md) | [1.3](/filings/0001193125-26-059193.md) | [2.6](/filings/0000950170-24-050478.md) | [0.1](/filings/0000950170-24-093580.md) | [0.1](/filings/0000950170-24-118821.md) | [0.7](/filings/0001193125-26-059193.md) | [0.1](/filings/0000950170-25-060940.md) | [0.2](/filings/0000950170-25-105060.md) | [0.1](/filings/0001193125-25-264566.md) | [0.1](/filings/0001193125-26-326001.md) | [0.3](/filings/0001193125-26-196029.md) | [0.1](/filings/0001193125-26-326001.md) |
| Current assets | $bn | [2.8](/filings/0000950170-23-057372.md) | [3.9](/filings/0000950170-25-024770.md) | [4.5](/filings/0000950170-24-050478.md) | [2.2](/filings/0000950170-24-093580.md) | [2.3](/filings/0000950170-24-118821.md) | [2.4](/filings/0001193125-26-059193.md) | [2.1](/filings/0000950170-25-060940.md) | [2.4](/filings/0000950170-25-105060.md) | [3.4](/filings/0001193125-25-264566.md) | [3.2](/filings/0001193125-26-326001.md) | [2.4](/filings/0001193125-26-196029.md) | [2.4](/filings/0001193125-26-326001.md) |
| Total assets | $bn | [14.9](/filings/0000950170-23-057372.md) | [15.1](/filings/0000950170-25-024770.md) | [16.2](/filings/0000950170-24-050478.md) | [16.3](/filings/0000950170-24-093580.md) | [16.5](/filings/0000950170-24-118821.md) | [18.2](/filings/0001193125-26-059193.md) | [17.7](/filings/0000950170-25-060940.md) | [18.1](/filings/0000950170-25-105060.md) | [18.7](/filings/0001193125-25-264566.md) | [18.7](/filings/0001193125-26-326001.md) | [20.5](/filings/0001193125-26-196029.md) | [21.3](/filings/0001193125-26-326001.md) |
| Current liabilities | $bn | [1.1](/filings/0000950170-23-057372.md) | [1.2](/filings/0000950170-25-024770.md) | [1.4](/filings/0000950170-24-050478.md) | [1.2](/filings/0000950170-24-093580.md) | [1.0](/filings/0000950170-24-118821.md) | [1.0](/filings/0001193125-26-059193.md) | [0.9](/filings/0000950170-25-060940.md) | [1.0](/filings/0000950170-25-105060.md) | [1.2](/filings/0001193125-25-264566.md) | [0.9](/filings/0001193125-26-326001.md) | [1.0](/filings/0001193125-26-196029.md) | [1.7](/filings/0001193125-26-326001.md) |
| Total liabilities | $bn | [7.1](/filings/0000950170-23-057372.md) | [7.1](/filings/0000950170-25-024770.md) | [7.4](/filings/0000950170-24-050478.md) | [7.5](/filings/0000950170-24-093580.md) | [7.3](/filings/0000950170-24-118821.md) | [8.7](/filings/0001193125-26-059193.md) | [8.6](/filings/0000950170-25-060940.md) | [8.7](/filings/0000950170-25-105060.md) | [8.9](/filings/0001193125-25-264566.md) | [8.7](/filings/0001193125-26-326001.md) | [9.2](/filings/0001193125-26-196029.md) | [9.8](/filings/0001193125-26-326001.md) |
| Long-term debt | $bn | [3.9](/filings/0000950170-23-057372.md) | [3.9](/filings/0000950170-25-024770.md) | [3.9](/filings/0000950170-24-050478.md) | [3.9](/filings/0000950170-24-093580.md) | [3.9](/filings/0000950170-24-118821.md) | [5.3](/filings/0001193125-26-059193.md) | [5.3](/filings/0000950170-25-060940.md) | [5.3](/filings/0000950170-25-105060.md) | [5.3](/filings/0001193125-25-264566.md) | [5.3](/filings/0001193125-26-326001.md) | [5.3](/filings/0001193125-26-196029.md) | [5.1](/filings/0001193125-26-326001.md) |
| Current portion of debt | $bn | [0.4](/filings/0000950170-23-057372.md) | [0.4](/filings/0000950170-25-024770.md) | [0.4](/filings/0000950170-24-050478.md) | [0.4](/filings/0000950170-24-093580.md) | [0.1](/filings/0000950170-24-118821.md) | [0.1](/filings/0001193125-26-059193.md) | [0.1](/filings/0000950170-25-060940.md) | [0.1](/filings/0000950170-25-105060.md) | [0.2](/filings/0001193125-25-264566.md) | [0.0](/filings/0001193125-26-326001.md) | [0.0](/filings/0001193125-26-196029.md) | [0.9](/filings/0001193125-26-326001.md) |
| Shareholders' equity | $bn | [7.8](/filings/0000950170-23-057372.md) | [8.0](/filings/0000950170-25-024770.md) | [8.9](/filings/0000950170-24-050478.md) | [8.8](/filings/0000950170-24-093580.md) | [9.2](/filings/0000950170-24-118821.md) | [9.5](/filings/0001193125-26-059193.md) | [9.1](/filings/0000950170-25-060940.md) | [9.4](/filings/0000950170-25-105060.md) | [9.7](/filings/0001193125-25-264566.md) | [10.0](/filings/0001193125-26-326001.md) | [11.3](/filings/0001193125-26-196029.md) | [11.5](/filings/0001193125-26-326001.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [454 d](/filings/0000950170-24-118821.md) | [555 d](/filings/0001193125-26-059193.md) | [172](/filings/0000950170-25-060940.md) | [1.0 d](/filings/0000950170-25-105060.md) | [600 d](/filings/0001193125-25-264566.md) | [686 d](/filings/0001193125-26-059193.md) | [218](/filings/0001193125-26-196029.md) | [387 d](/filings/0001193125-26-326001.md) | [551 d](/filings/0001193125-25-264566.md) | [629 d](/filings/0001193125-26-059193.md) | [227](/filings/0001193125-26-196029.md) | [112 d](/filings/0001193125-26-326001.md) |
| Capital expenditure | $m | [171 d](/filings/0000950170-24-118821.md) | [186 d](/filings/0001193125-26-059193.md) | [200](/filings/0000950170-25-060940.md) | [139 d](/filings/0000950170-25-105060.md) | [283 d](/filings/0001193125-25-264566.md) | [233 d](/filings/0001193125-26-059193.md) | [233](/filings/0001193125-26-196029.md) | [179 d](/filings/0001193125-26-326001.md) | [190 d](/filings/0001193125-25-264566.md) | [205 d](/filings/0001193125-26-059193.md) | [186](/filings/0001193125-26-196029.md) | [128 d](/filings/0001193125-26-326001.md) |
| Dividends paid | $m | [45.0 d](/filings/0000950170-24-118821.md) | [46.0 d](/filings/0001193125-26-059193.md) | [46.0](/filings/0000950170-25-060940.md) | [46.0 d](/filings/0000950170-25-105060.md) | [49.0 d](/filings/0001193125-25-264566.md) | [48.0 d](/filings/0001193125-26-059193.md) | [49.0](/filings/0001193125-26-196029.md) | [48.0 d](/filings/0001193125-26-326001.md) | [50.0 d](/filings/0001193125-25-264566.md) | [50.0 d](/filings/0001193125-26-059193.md) | [51.0](/filings/0001193125-26-196029.md) | [51.0 d](/filings/0001193125-26-326001.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-24-118821.md) | [0.0 d](/filings/0001193125-26-059193.md) | [150](/filings/0000950170-25-060940.md) | [300 d](/filings/0000950170-25-105060.md) | [0.0 d](/filings/0001193125-25-264566.md) | [0.0 d](/filings/0001193125-26-059193.md) | [450](/filings/0001193125-26-196029.md) | [0.0 d](/filings/0001193125-26-326001.md) | [0.0 d](/filings/0001193125-25-264566.md) | [0.0 d](/filings/0001193125-26-059193.md) | [200](/filings/0001193125-26-196029.md) | [0.0 d](/filings/0001193125-26-326001.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [62.5](/filings/0000950170-23-057372.md) | [62.2](/filings/0000950170-24-050478.md) | [62.1](/filings/0000950170-24-093580.md) | [62.0](/filings/0000950170-24-118821.md) | [62.0](/filings/0000950170-25-060940.md) | [61.6](/filings/0000950170-25-105060.md) | [61.3](/filings/0001193125-25-264566.md) | [61.0](/filings/0001193125-26-196029.md) | [60.4](/filings/0001193125-26-326001.md) | [60.4](/filings/0001193125-25-264566.md) | [60.4](/filings/0001193125-26-196029.md) | [60.2](/filings/0001193125-26-326001.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 60,065,839 at 2026-07-27, from the cover of the [10-Q filed 2026-07-30](/filings/0001193125-26-326001.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.